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Background: Chronic actinic dermatitis (CAD) is an idiopathic photosensitive dermatosis induced by
ultraviolet B (UVB), sometimes ultraviolet A (UVA), and occasionally visible light. Diagnosis is suggested
by the clinical ﬁndings, typically a chronic eczematous rash on the sun exposed areas, and conﬁrmed by
phototesting, which demonstrates the abnormal photosensitivity. The aim of this study was to determine
the characteristics of CAD in Taiwanese patients.
Methods: We retrospectively reviewed the clinical and photobiological features of all patients diagnosed
as having CAD at our institute from 2002 to 2012.
Results: A total of 15 patients with CAD were identiﬁed. The mean age at diagnosis was 58.6 years (range,
28e82 years). All the patients were males. The face, neck, forearms, and dorsal hands were most
commonly involved. Eight patients (53.3%) had decreased minimal erythema dose (MED) to both UVB
and UVA; six patients (40.0%) had decreased MED to only UVB; one patient (6.7%) had decreased MED to
only UVA. All were managed with photoprotection and topical corticosteroids. Four patients received
azathioprine (50 mg twice a day to every other day) and one received prednisolone (10 mg per day to
every other day).
Conclusion: In Taiwan, CAD affects elderly men more commonly. The most common phototest results
were decreased MED to both UVB and UVA, followed by to UVB alone. All patients were managed with
photoprotection and topical corticosteroids, and some also required systemic agents, in particular
azathioprine.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.8Introduction
Chronic actinic dermatitis (CAD), an idiopathic photosensitive
dermatosis, is an eczema of the exposed areas induced by UVB,
sometimes UVA, and occasionally visible light.1 The term was
originally introduced by Hawk and Magnus in 1979;2 persistent
light reactivity, actinic reticuloid, photosensitive eczema, and
photosensitivity dermatitis are all considered variants of CAD.3,4
Earlier investigations of CAD were mostly from countries with
temperate climates. However, the disease appears to have world-
wide distribution and affects all skin types. It has also been re-
ported from subtropical or tropical regions, such as Australia,5
India,6 and Singapore.7 As diagnostic phototesting facilities are
limited to only a few medical centers in Taiwan, CAD status iny have no ﬁnancial or non-
tter or materials discussed in
y, National Taiwan University
an.
iwanese Dermatological AssociatioTaiwan has never been studied. Here, we collected cases of pho-
totesting proven CAD in our institute and reported the clinical
features, photobiological characteristics, histological ﬁndings, and
treatment in a Taiwanese population.
Methods
This was a retrospective analysis of medical records of phototested
cases at the National Taiwan University Hospital, Taipei, Taiwan
from January 2002 to August 2012. Information concerning their
age, gender, clinical manifestations, phototesting results, histopa-
thology, laboratory tests, and treatment was obtained for review.
The diagnosis of CAD was based on the following criteria:5 (1) a
persistent dermatitis in photodistributed areas without a history of
exposure to a known topical or systemic photosensitizer; (2) a
reduced minimal erythema dose (MED) to UVB or UVA or both on
phototesting: MED to UVB  100 mJ/cm2,9 MED to UVA  15 J/
cm2;10 (3) histology of the lesional skin, when available, showing
chronic eczema, with or without cutaneous T cell lymphoma-like
changes; and (4) no clinical/laboratory evidence of othern. Published by Elsevier Taiwan LLC. All rights reserved.
T.-L. Hsiao, C.-Y. Chu / Dermatologica Sinica 32 (2014) 82e86 83autoimmune diseases with photosensitivity such as lupus erythe-
matosus or dermatomyositis.
Phototesting was performed using the following light sources: a
UV 801 KL (Waldmann, Villingen-Schwenningen, Germany)
equipped with four TL 20 W/12 ﬂuorescent tubes (spectral output
285e350 nm, peak 310e315 nm; Philips, Eindhoven, The
Netherlands) for UVB and six UV-A Cleo 40 W ﬂuorescent tubes
(spectral output 315e400 nm, peak 355e365 nm; Philips) for UVA.
The back of each patient was exposed to ﬁve graded doses of UVB
ranging from20mJ/cm2 to 100mJ/cm2, with an increment of 20mJ/
cm2 and ﬁve graded doses of UVA ranging from 3 J/cm2 to 15 J/cm2,
with an increment of 3 J/cm2. The MED was deﬁned as the smallest
exposure dose required to produce a minimally perceptible ery-
thema with well demarcated borders. Erythema responses were
read 24 hours after irradiation; if no response was observed at 24
hours, a second reading at 48 hours would be taken.3e9 If needed, a
photopatch test was performed according to the guidelines of the
International Contact Dermatitis Research Group11 to exclude
photosensitive dermatitis or photoallergic contact dermatitis.Results
Patient characteristics
A total of 15 patients with CAD were identiﬁed. The mean age at
diagnosis was 58.6 years (range, 28e82 years). Most patients
(>85%) had CAD after age 40 years. All the patients were males.
Among the 15 patients, none of them were Fitzpatrick’s skin pho-
totype I, II, or VI. Three patients were phototype III, 10 patients were
phototype IV, and two patients were phototype V. All 15 patients
were Han Chinese. The interval between disease onset and diag-
nosis of CAD conﬁrmed by phototesting ranged from 1 month to >
10 years. Demographic data are presented in Table 1 and Figure 1.Clinical manifestations
The distribution of the eruptions, as shown in Figure 2, was char-
acteristically located on the sun-exposed areas. The face (93%) was
the most commonly affected, followed by the dorsal hands (80%),
arms (73%), and neck (60%; Figure 3). Themorphology of the lesions
included papules, patches, and plaques. Most were described as
scaly or licheniﬁed lesions. Itching was the most common
symptom.Table 1 Clinical and pathological data of the 15 cases.
No. Age Sex Int Occupation Histopathology MED
1 51 M 4 y Construction NA Y
2 28 M 2 y NA NA e
3 75 M 1 y NA NA e
4 50 M 2 mo Postman Superﬁcial dermatitis e
5 59 M 1 mo NA NA Y
6 59 M 3 y Salesman Chronic cheilitis e
7 71 M 10 y NA NA Y
8 40 M 3 y Clerk NA e
9 45 M 1 y Construction NA Y
10 50 M 1 y Salesman NA Y
11a 61 M 3 y Carpenter Hypersensitivity reaction e
12 69 M 5 y Farmer NA Y
13 74 M 10 y NA Chronic dermatitis Y
14 66 M 1 mo Businessman NA Y
15 82 M 1 y NA NA Y
AZT¼ azathioprine; BD¼ betamethasone dipropionate; bid¼ twice a day; BV¼ betameth
qod¼ every other day; H¼ hydrocortisone; Int¼ interval between disease onset and diag
NA ¼ not applicable; P ¼ pimecrolimus.
a Patient 11 has been reported previously.8Phototesting results
Eight patients (53.3%) had decreased MED to both UVB and UVA;
six patients (40.0%) had decreased MED to only UVB; one patient
(6.7%) had decreased MED to only UVA (Figure 4).
Histopathology
Four patients had skin biopsies taken from areas of existing
dermatitis. The pathology reports showed superﬁcial dermatitis,
chronic dermatitis, hypersensitivity reaction compatible with
allergic contact dermatitis, and chronic cheilitis, respectively.
Management
All patients were advised to ensure sun protection andwere treated
with topical corticosteroids. Most required medium to high po-
tency topical corticosteroids for disease control initially. One pa-
tient received topical pimecrolimus for facial rash. Four patients
received oral azathioprine treatment: the doses ranged from 50 mg
twice a day to every other day, and the duration ranged from 2
weeks to > 2 years. Two of the patients were lost to follow-up 2e3
weeks after the use of the medication. Azathioprine was dis-
continued after 3 weeks in one patient due to nausea and vomiting.
Another patient received prednisolone 10 mg/day for 24 days and
then 10 mg every other day for 16 weeks with remarkable initial
improvement but the patient was lost to follow-up thereafter.
Discussion
The diagnosis of CAD is suggested by the clinical ﬁndings, most
commonly a chronic eczematous rash on the sun exposed areas,
and corroborated by phototesting, which characterizes the action
spectrum and degree of photosensitivity. When necessary, histol-
ogy of the lesional skin is used to exclude other disorders. In this
study, we retrospectively reviewed the clinical features, phototest
results, and treatment of CAD in a Taiwanese population. Our study
showed that CAD commonly affected elderly men, with a remark-
able male predominance and a mean age at diagnosis of 58.6 years,
in line with previous reports.3,5,7,12,13 The lack of female patients in
this study might be due to the small sample size. There has been
evidence that CAD may occur in young patients with atopic
dermatitis;14 however, the patient in our study who presented the
disease at a relatively young age (Patient 2, age 28 years) did notA MED B Treatment
Y C, F, BV, H, P
Y D
Y F
Y D, H
Y C, F, H
Y AZT 50 mg bid to qod for > 2 y
Y AZT 50 mg bid for 2 wk/ LFU
Y C
Y AZT 50 mg qd for 3 wk, DC due to nausea and vomiting/ C
Y C, F
Y C, D, H, BD
Y AZT 50 mg qd for 2 wk/ LFU
e Prednisolone 10 mg qd for 24 d/ 10 mg qod for 16 wk/ LFU
Y C, F, H
Y C, D, F, BD
asone valerate; C¼ clobetasol; D¼ desoximetasone; F¼ ﬂuticasone; qd¼ each day;
nosis of CAD; LFU¼ loss of follow-up; MED A ¼MED to UVA; MED B¼MED to UVB;
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Figure 1 Age distribution of disease onset.
T.-L. Hsiao, C.-Y. Chu / Dermatologica Sinica 32 (2014) 82e8684have atopic diathesis. Immunoglobulin (Ig)E level was measured in
three of the patients. Patient 2 had an IgE level of < 2 IU/mL. Pa-
tients 7 and 11 had slightly elevated IgE levels of 329 IU/mL and
170 IU/mL, respectively (normal range, 0e100 IU/mL).
Some authors have noticed an association between increased
sun exposure and CAD.13 Therefore, we also list the occupation of
these patients in Table 1.
Abnormal photosensitivity is the hallmark of CAD. Historically, it
has been suggested that all CAD patients have a reduced MED to
UVB, the majority also have a reduced MED to UVA, and a minority
respond to the visible wavelengths as well.1 In addition, UVA
sensitivity dissociated from UVB sensitivity has been implicated as
a relative indicator of drug induced photosensitivity15 or photo-
allergic contact dermatitis (PACD).1 However, lowered MED to UVA
only in otherwise typical CAD cases has been increasingly re-
ported.3,12 In our study, the majority of the patients (53.3%) had
reduced MED to both UVB and UVA, in keeping with the common
observations in the literature. Interestingly, a signiﬁcant portion
(40.0%) of our patients had reduced MED to only UVB, compared
with just 6.7% to only UVA. This was similar to the study results in
Singaporean and Korean populations.7,13 By contrast, other studies
found reduced MED to only UVA more common than reduced MED
to only UVB in the Greek,16 Australian,5 and United States17 pop-
ulations. The reason for the discrepancy remains unclear and ethnic
or geographical factors may contribute to it.0
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Figure 2 Distribution of the involved areas.Patch and photopatch tests are ancillary tools in patients with
suspected CAD to exclude allergic contact dermatitis (ACD) and
PACD. Up to 75% CAD patients were reported to have positive re-
actions in patch or photopatch tests.18 In our institute, we do not
perform patch and photopatch tests routinely if the patient does
not have a history of exposure to an allergen or photosensitizer.
This is a shortage that the possibility of ACD/PACD or concurrent
ACD/PACD and CAD cannot be excluded in this study. Patient 11was
a construction worker having contact history to formaldehyde and
melamine; patch testing with the standard tray and his contactantsFigure 3 Clinical pictures. (A) Patient 7 showing inﬁltrated eczematous eruptions on
the face: the folds and creases are relatively spared. (B) Close view of forehead lesions:
the creases and upper eyelids are relatively spared. (C) Patient 11: a clear cut-off where
clothing begins is often seen on the arms.
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Figure 4 Comparison between the phototest features of chronic actinic dermatitis and
patients of different countries.
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sulfate. Patient 13 also received photopatch tests in order to exclude
drug-induced photosensitivity and PACD and the results were
negative.
The etiology of CAD is still not well understood. Evidence sug-
gests that CAD is a delayed type hypersensitivity reaction to
endogenous photoinduced antigens.1 The action spectrum for CAD
has been shown to resemble that for sunburn in normal in-
dividuals,19 for which the chromophore is considered to be DNA.
This implicates DNA or a similar or related molecule being the
presumed photoallergen. Additionally, the prevalence of coexisting
contact or photocontact allergy in CAD patients may play a role in
CAD pathogenesis. Certain contact allergens, such as fragrance
materials and colophony, which are potentially phototoxic, may be
able to convert endogenous proteins into allergens.1 Another hy-
pothesis proposes that a failure in the normal suppression of
delayed type hypersensitivity by UV irradiation may be involved.1 It
is likely that combinations of some of the aspects account for the
pathogenesis of CAD.
The abnormal photosensitivity of CAD may resolve in a signiﬁ-
cant proportion of patients. Dawe et al20 reported that the proba-
bility of resolution of photosensitivity in 5 years, 10 years, and 15
years is 7%, 22%, and 45% respectively. Severe UVB photosensitivity
and allergy to two or more patch test series are indicators for a poor
prognosis.20
All CAD patients should be advised to avoid UV exposure and
contact with associated allergens or photoallergens. The approach
to topical treatment is as for other dermatitis conditions. Topical
corticosteroids are often required, and successful responses to
topical tacrolimus21,22 and pimecrolimus23 have also been reported.
For severe or refractory cases, phototherapy or systemic immuno-
modulators may be required. Psoralen combined with UVA and
narrow band UVB have been shown to be effective in some cases,
particularly with the use of systemic corticosteroids, cyclosporine,
or other immunosuppressants to assist tolerance in the early pha-
ses of treatment.24e26 Azathioprine is the only therapeutic agent
that has been evaluated in a double blinded, placebo controlled trial
among the various treatment options for CAD.27 Remission has
been demonstrated in two-thirds of patients after receiving
azathioprine 100e150 mg daily for several months.27 Cyclo-
sporine,28 mycophenolate,29 methotrexate,5 hydroxyurea,30thalidomide,31 hydroxychloroquine,12 etretinate,12 and danazol32
have been reported to be beneﬁcial in a number of cases. Suc-
cessful management with dermabrasion in a CAD patient not
responsive to topical and local corticosteroids and other immuno-
suppressants has also been reported.33
In conclusion, we showed that CAD in Taiwan affects elderly
men more commonly and decreased MED to both UVB and UVA is
the most frequent photobiological feature. Because our ﬁndings are
based on the retrospective analysis of a limited number of cases,
further investigations may be needed to conﬁrm the results from
the present study.
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